When used in vivo ibrutinib exhibits a profound effect and promotes rapid resolution of lymphadenopathy coupled with lymphocytosis of CLL cells [152, 157], presumably by inhibiting the ability of BCR to activate integrin α4β1 and maintain the adhesion required for their residence within proliferation centers [3, 130]. Here, BCR is linked to B-cell chronic lymphocytic leukemia.